Anti-CD20 Antibody Formulation Glycoengineering ADCC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD20 monoclonal antibodies have limitations in their binding modes and biological activities, such as varying efficacy in complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity, which affect their therapeutic outcomes in treating CD20-expressing cancers like B-cell non-Hodgkin's lymphomas.
Innovation Solution
Development of a specific anti-CD20 monoclonal antibody formulation with optimized binding properties, including a ratio of binding capacities to CD20 on Raji cells compared to rituximab, and enhanced antibody-dependent cellular cytotoxicity through glycoengineering, which increases ADCC activity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-CD20 monoclonal antibodies are used, then complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity are achieved, but therapeutic efficacy is limited due to varying binding modes and biological activities
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's glycosylation pattern (specifically reducing fucose content in the Fc region) to enhance ADCC activity. This chemical modification of the antibody structure changes its biological properties, allowing it to more effectively engage NK cells and improve therapeutic efficacy while maintaining consistent binding characteristics
Solution Approach 2:
The invention creates a composite functional structure by combining the anti-CD20 binding region with an optimized Fc region that has engineered glycosylation characteristics. This composite approach integrates two distinct functional elements: the antigen-specific binding capability and the enhanced effector function through modified glycan structures, resulting in an antibody with superior and more consistent therapeutic performance
2Productivity
If antibody concentration is increased to improve therapeutic outcome, then response rates and survival duration increase, but formulation stability and aggregation control become more difficult
Solution Approach 1:
The patent employs parameter changes by optimizing formulation conditions including pH, ionic strength, and the addition of stabilizing excipients such as surfactants and sugars. These parameter adjustments prevent aggregation and maintain antibody stability at higher concentrations, enabling improved therapeutic outcomes without compromising formulation integrity
Solution Approach 2:
The invention introduces intermediary substances (excipients such as polysorbate 80, histidine buffer, and trehalose) that act as mediators between the antibody and the formulation environment. These intermediaries protect the antibody from aggregation and degradation, allowing the formulation to maintain stability at high concentrations required for effective therapy
Data Source
AI summary
The present invention relates to an anti-CD20 human monoclonal antibody formulation, a process for the preparation and uses thereof.